Status:

COMPLETED

Nasal Decongestion and Obstructive Sleep Apnea

Lead Sponsor:

University of Zurich

Conditions:

Obstructive Sleep Apnea Syndrome

Rhinitis

Eligibility:

All Genders

20-75 years

Phase:

PHASE4

Brief Summary

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that dec...

Eligibility Criteria

Inclusion

  • Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index \>10/h)
  • Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)

Exclusion

  • Nasal surgery within the last 6 months
  • Current treatment with nasal decongestants or topical steroids
  • Sleep disorders other than obstructive sleep apnea
  • Internal medical or psychiatric disorders that interfered with sleep

Key Trial Info

Start Date :

January 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2005

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00630474

Start Date

January 1 2004

End Date

April 1 2005

Last Update

December 23 2009

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Pulmonary Division, University Hospital Zurich, Switzerland

Zurich, Switzerland, CH-8091

2

Pulmonary Division, University Hospital Zurich

Zurich, Switzerland, CH-8091